Last reviewed · How we verify
AAV2-sFLT01
VEGF inhibitor
VEGF inhibitor Used for Age-related macular degeneration.
At a glance
| Generic name | AAV2-sFLT01 |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | VEGF inhibitor |
| Target | VEGFR |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AAV2-sFLT01 is a gene therapy that uses adeno-associated virus 2 (AAV2) to deliver the soluble fms-like tyrosine kinase-1 (sFLT01) gene, which encodes a soluble form of the VEGF receptor. This leads to the inhibition of vascular endothelial growth factor (VEGF), a protein involved in angiogenesis and tumor growth.
Approved indications
- Age-related macular degeneration
Common side effects
- Intraocular inflammation
- Increased intraocular pressure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |